Regencell Bioscience (NASDAQ:RGC) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of Regencell Bioscience (NASDAQ:RGC) from a hold rating to a sell rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Regencell Bioscience currently has a consensus rating of “Sell”.

Regencell Bioscience Trading Up 5.0%

NASDAQ:RGC opened at $5.02 on Friday. Regencell Bioscience has a 12 month low of $4.51 and a 12 month high of $69.00. The firm has a fifty day simple moving average of $16.25 and a 200-day simple moving average of $24.13.

Regencell Bioscience (NASDAQ:RGC) last released its earnings results on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Trading of Regencell Bioscience

A number of hedge funds and other institutional investors have recently made changes to their positions in RGC. Seven Fleet Capital Management LP purchased a new stake in Regencell Bioscience in the 4th quarter worth approximately $92,000. Amundi acquired a new stake in shares of Regencell Bioscience during the 1st quarter worth approximately $219,000. Vident Advisory LLC increased its holdings in shares of Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after purchasing an additional 11,866 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Regencell Bioscience during the 4th quarter valued at approximately $275,000. Finally, Bank of America Corp DE lifted its stake in shares of Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after purchasing an additional 17,143 shares during the period. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.